J.P. Delord

1.4k total citations
48 papers, 981 citations indexed

About

J.P. Delord is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, J.P. Delord has authored 48 papers receiving a total of 981 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in J.P. Delord's work include Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Melanoma and MAPK Pathways (5 papers). J.P. Delord is often cited by papers focused on Colorectal Cancer Treatments and Studies (10 papers), Lung Cancer Treatments and Mutations (7 papers) and Melanoma and MAPK Pathways (5 papers). J.P. Delord collaborates with scholars based in France, Switzerland and United States. J.P. Delord's co-authors include Karim Fizazi, A. Le Cesne, Laurent Zelek, O. Rixe, M. Riofrio, M. Spielmann, Antoîne Italiano, Christine Chevreau, Christophe Le Tourneau and Bettina Couderc and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

J.P. Delord

47 papers receiving 973 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.P. Delord France	18	706	276	253	162	117	48	981
Ritesh Rathore United States	15	837 1.2×	242 0.9×	217 0.9×	113 0.7×	239 2.0×	44	1.0k
Yasir Y. Elamin United States	16	595 0.8×	518 1.9×	284 1.1×	164 1.0×	71 0.6×	68	968
Anastasia G Eleftheraki Greece	20	612 0.9×	316 1.1×	357 1.4×	240 1.5×	107 0.9×	37	1.2k
Marc Ballas United States	14	554 0.8×	336 1.2×	254 1.0×	98 0.6×	144 1.2×	46	905
Tyler P. Robin United States	17	608 0.9×	405 1.5×	330 1.3×	198 1.2×	69 0.6×	55	1.3k
Hui‐Lan Rao China	20	664 0.9×	218 0.8×	259 1.0×	142 0.9×	222 1.9×	44	1.1k
Marius Lund‐Iversen Norway	17	499 0.7×	523 1.9×	279 1.1×	162 1.0×	169 1.4×	60	1.0k
Sergi Benavente Spain	15	931 1.3×	545 2.0×	523 2.1×	190 1.2×	88 0.8×	33	1.4k
Catherine Park United States	8	380 0.5×	312 1.1×	210 0.8×	295 1.8×	63 0.5×	11	926
Stephanie Petrillo Canada	18	293 0.4×	118 0.4×	394 1.6×	216 1.3×	94 0.8×	38	794

Countries citing papers authored by J.P. Delord

Since Specialization

Citations

This map shows the geographic impact of J.P. Delord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.P. Delord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.P. Delord more than expected).

Fields of papers citing papers by J.P. Delord

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.P. Delord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.P. Delord. The network helps show where J.P. Delord may publish in the future.

Co-authorship network of co-authors of J.P. Delord

This figure shows the co-authorship network connecting the top 25 collaborators of J.P. Delord. A scholar is included among the top collaborators of J.P. Delord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.P. Delord. J.P. Delord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2022). LBA33 5-year overall survival (OS) in patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) treated with xevinapant + chemoradiotherapy (CRT) vs placebo + CRT in a randomized, phase II study. Annals of Oncology. 33. S1400–S1400. 6 indexed citations

Italiano, Antoine, Josep Tabernero, Mariano Provencio, et al.. (2022). 490P Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). Annals of Oncology. 33. S764–S765. 3 indexed citations

Delord, J.P., et al.. (2022). 676P ATHENA: A multicenter phase II of atezolizumab (A) and bevacizumab (B) in patients (pts) with recurrent or metastatic squamous-cell carcinoma of the head and neck (R/M HNSCC) - The HPV-negative cohort. Annals of Oncology. 33. S851–S852. 1 indexed citations

Lu, Janice, Collin M. Blakely, Minal Barve, et al.. (2022). 173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2. Annals of Oncology. 33. S204–S205. 1 indexed citations

Bourhis, Jean, C. Le Tourneau, Y. Pointreau, et al.. (2020). LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. Annals of Oncology. 31. S1168–S1168. 5 indexed citations

Tourneau, Christophe Le, Philippe A. Cassier, Frédéric Rolland, et al.. (2020). 63MO TG4001 therapeutic vaccination combined with PD-L1 blocker avelumab remodels the tumor microenvironement (TME) and drives antitumor responses in human papillomavirus (HPV)+ malignancies. Annals of Oncology. 31. S1442–S1442. 5 indexed citations

Domchek, S. M., Sophie Postel‐Vinay, Y-J. Bang, et al.. (2018). Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated (g BRCA m) HER2-negative metastatic breast cancer (MBC). Cancer Research. 78(4_Supplement). PD6–11. 41 indexed citations

Díaz, Luis A., Aurélien Marabelle, T.W. Kim, et al.. (2017). Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Annals of Oncology. 28. v128–v129. 52 indexed citations

Khalifa, Jonathan, M. Ouali, Léonor Chaltiel, et al.. (2015). Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 15(1). 700–700. 36 indexed citations

10.

Tabernero, Josep, Robin M.J.M. van Geel, Anna Spreafico, et al.. (2014). 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer. European Journal of Cancer. 50. 199–199. 9 indexed citations

11.

Castells, Mariana, Delphine Milhas, Benoît Thibault, et al.. (2013). Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death and Disease. 4(10). e887–e887. 53 indexed citations

12.

Delord, J.P., Nicolás Isambert, P. Fumoleau, et al.. (2011). Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer.. Journal of Clinical Oncology. 29(15_suppl). 2570–2570. 1 indexed citations

13.

Delord, J.P., Stéphane Quideau, Philippe Rochaix, et al.. (2010). Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model. British Journal of Cancer. 103(1). 61–72. 11 indexed citations

14.

Mesı́a, Ricard, Fernando Rivera, Andrzej Kawecki, et al.. (2010). Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 21(10). 1967–1973. 78 indexed citations

15.

Sibaud, V., J.P. Delord, & Christine Chevreau. (2009). Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?. Targeted Oncology. 4(4). 307–310. 22 indexed citations

16.

Delord, J.P., Marie‐Jeanne Pillaire, Philippe Rochaix, et al.. (2008). Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. British Journal of Cancer. 98(1). 120–128. 42 indexed citations

17.

Delord, J.P., Jaafar Bennouna, Pascal Artru, et al.. (2007). Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer. British Journal of Cancer. 97(3). 297–301. 13 indexed citations

18.

Zelek, Laurent, M. Riofrio, Karim Fizazi, et al.. (2001). Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer. 92(9). 2267–2272. 122 indexed citations

19.

Merimsky, Ofer, C. Lepéchoux, Philippe Terrier, et al.. (2000). Primary Sarcomas of the Central Nervous System. Oncology. 58(3). 210–214. 35 indexed citations

20.

Soulié, P, Hassan Errihani, Anne Bessard, et al.. (1997). 6-day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. Journal of Cancer Research and Clinical Oncology. 123(4). 227–231. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact